Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GLAUKOS CorpGKOS · Entity 3510 | Director | May 28, 2026 | June 23, 2026 |
| SI-BONE, Inc.SIBN · Entity 2501 | Director | June 16, 2020 | June 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GLAUKOS Corp
Report date May 28, 2026 · Filed June 23, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.52 · Expires 2036-05-28 | Direct | 2,987 |
Reported balance
After 2026-05-28 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 2,987 · Balance 2,987 F1: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. F2: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above.
F2: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.
SI-BONE, Inc.
Report date June 16, 2020 · Filed June 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,797 |
Reported balance
After 2020-06-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-06-16 · Grant · Acquired 8,797 · Balance 8,797 F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2: Includes 8,797 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date.
F2: Includes 8,797 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Revance Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-06 transaction · row 5
4 source rows · reconciled sequenceRow 1 · 2025-02-04 · Other · Disposed 996,935 · Balance 27,933 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 3 · 2025-02-06 · Disposition to issuer · Disposed 27,933 · Balance 0 F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement). Row 4 · 2025-02-06 · Grant · Acquired 84,686 · Balance 84,686 F4: Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, pursuant to the terms of the Merger Agreement. Row 5 · 2025-02-06 · Disposition to issuer · Disposed 84,686 · Balance 0 F5: Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement). |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-02-04 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-04 · Other · Disposed 110,913 · Balance 0 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. F2: These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2: These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.
F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement).
F4: Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, pursuant to the terms of the Merger Agreement.
F5: Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement).
Zeltiq Aesthetics Inc
Report date April 28, 2017 · Filed April 28, 2017
Section 16 reporting ended · disclosed 2017-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Disposition to issuer · Disposed 173,787 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 173,787 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2022-08-23 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-04-28 · Disposition to issuer · Disposed 572,435 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2022-08-23 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-04-28 · Disposition to issuer · Disposed 758,667 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.06 · Expires 2022-06-14 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-04-28 · Disposition to issuer · Disposed 9,536 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2022-04-27 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-04-28 · Disposition to issuer · Disposed 121,236 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.00 · Expires 2024-02-24 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-04-28 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.65 · Expires 2025-02-18 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-04-28 · Disposition to issuer · Disposed 26,277 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2026-02-27 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-04-28 · Disposition to issuer · Disposed 124,610 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.89 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-04-28 · Disposition to issuer · Disposed 72,254 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 173,787 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed Jun 1, 2026 22:18 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 2,987 | $0.00 Strike: $53.57 | $0.00 |
DisclosureSEC source: 0001529196-26-000004 · form4-06012026_100644.xml · derivative · entry 2 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,987 Underlying: Common Stock · 2,987 shares Expires 2036-05-28 F3 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 22:18 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001529196-26-000004 · form4-06012026_100644.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,267 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 5,154 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| May 28, 2026 Filed Jun 23, 2026 23:29 UTC Amendment | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 2,987 | $0.00 Strike: $106.52 | $0.00 |
DisclosureSEC source: 0001529196-26-000006 · form4a-06232026_110617.xml · derivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,987 Underlying: Common Stock · 2,987 shares Expires 2036-05-28 F1 · derivative.exercise_price: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. F2 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| January 02, 2026 Filed Jan 8, 2026 00:10 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001529196-26-000002 · form4-01082026_120132.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,389 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 3,276 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:44 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 3,149 | $0.00 Strike: $94.87 | $0.00 |
DisclosureSEC source: 0001415889-25-015178 · form4-06022025_080609.xml · derivative · entry 3 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,149 Underlying: Common Stock · 3,149 shares Expires 2035-05-29 F5 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:44 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015178 · form4-06022025_080609.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,221 F3 · security: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F4 · balance_after: Includes 4,688 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:57 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001415889-25-006046 · form4-02282025_100208.xml · derivative · entry 5 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Granted June 2, 2016 and fully vested one year after grant date. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:57 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $32.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006046 · form4-02282025_100208.xml · derivative · entry 4 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Granted July 23, 2015. Vested 1/3 annually over a three-year period such that it vested in full on the three-year anniversary of the grant date. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:57 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 20,687 | $120.72 | $2,497,334.64 |
DisclosureSEC source: 0001415889-25-006046 · form4-02282025_100208.xml · nonDerivative · entry 3 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,249 F2 · price: This transaction was executed in multiple trades at prices ranging from $120.59 to $121.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 1,716 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:57 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 15,000 | $24.69 | $370,350.00 |
DisclosureSEC source: 0001415889-25-006046 · form4-02282025_100208.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,716 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:57 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 25,000 | $32.00 | $800,000.00 |
DisclosureSEC source: 0001415889-25-006046 · form4-02282025_100208.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,716 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:59 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Disposition to issuerCommon Stock | 84,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015363 · ownership.xml · nonDerivative · entry 5 Foley Mark J · CIK 0001529196 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · price: Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement). Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:59 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 84,686 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-015363 · ownership.xml · nonDerivative · entry 4 Foley Mark J · CIK 0001529196 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,686 F4 · shares: Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, pursuant to the terms of the Merger Agreement. Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:59 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Disposition to issuerCommon Stock | 27,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015363 · ownership.xml · nonDerivative · entry 3 Foley Mark J · CIK 0001529196 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement). Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 15:59 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 110,913 | $3.65 | $404,832.45 |
DisclosureSEC source: 0000950170-25-015363 · ownership.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. F2 · ownership.nature: These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 15:59 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 996,935 | $3.65 | $3,638,812.75 |
DisclosureSEC source: 0000950170-25-015363 · ownership.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,933 F1 · kind: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 19:53 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 27,933 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-014825 · ownership.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,024,868 F1 · shares: Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 3, 2025, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on (i) the achievement of a revenue goal, measured beginning January 1, 2024 through December 31, 2024, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date. Read SEC document |
| January 02, 2025 Filed Jun 2, 2025 20:44 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 864 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015178 · form4-06022025_080609.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,800 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 2,580 restricted stock units that have not vested or been delivered to the Reporting Person. Reflects the amount of securities beneficially owned by the Reporting Person at the time of the transaction; after giving effect to the transactions reported on a Form 4 filed with the Securities and Exchange Commission on February 28, 2025, the amount of securities beneficially owned by the Reporting Person was 55,113. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 16:33 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 1,000 | $2.18 | $2,184.50 |
DisclosureSEC source: 0001479290-25-000004 · wk-form4_1735940017.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 996,935 F1 · shares: These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on December 31,2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 17:47 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 1,000 | $2.18 | $2,184.50 |
DisclosureSEC source: 0001479290-24-000104 · wk-form4_1719956853.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 995,935 F1 · shares: These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30,2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 00:56 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 1,246 | $0.00 Strike: $110.70 | $0.00 |
DisclosureSEC source: 0001415889-24-015236 · form4-06042024_120612.xml · derivative · entry 2 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,246 Underlying: Common Stock · 1,246 shares Expires 2034-05-30 F3 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 00:56 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015236 · form4-06042024_120612.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,936 F1 · security: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 4,946 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 18:43 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 17,228 | $5.31 | $91,394.54 |
DisclosureSEC source: 0001479290-24-000065 · wk-form4_1710888177.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994,935 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 18:43 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 3,305 | $5.31 | $17,533.03 |
DisclosureSEC source: 0001479290-24-000065 · wk-form4_1710888177.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,012,163 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the "RSA") for 13,572 shares. The RSA vested in three equal annual installments from March 15, 2021. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 16:33 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | PurchaseCommon Stock | 30,000 | $6.98 | $209,400.00 |
DisclosureSEC source: 0001479290-24-000056 · wk-form4_1709933576.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,015,468 F1 · shares: The reporting person purchased shares of common stock in an underwritten public offering by the issuer that closed on March 6, 2024. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 16:33 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 70,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-24-000050 · wk-form4_1709587601.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 985,468 F1 · shares: Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 29, 2024, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on (i) the achievement of a revenue goal, measured beginning January 1, 2023 through December 31, 2023, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date of March 15, 2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 00:01 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001415889-24-005327 · form4-02272024_120257.xml · derivative · entry 3 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Granted July 10, 2014. Vested 1/3 annually over a three-year period such that it vested in full on the three-year anniversary of the grant date. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 00:01 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 4,560 | $92.87 | $423,487.20 |
DisclosureSEC source: 0001415889-24-005327 · form4-02272024_120257.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,220 F2 · price: This transaction was executed in multiple trades at prices ranging from $92.75 to $92.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 3,230 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 00:01 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 10,000 | $7.28 | $72,750.00 |
DisclosureSEC source: 0001415889-24-005327 · form4-02272024_120257.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 3,230 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 16:45 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantPerformance Stock Units · Derivative | 1,070,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-24-000014 · wk-form4_1706910313.xml · derivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,070,001 Underlying: Common Stock · 1,070,001 shares Expires 2028-01-31 F1 · security: The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates. F1 · derivative.exercise_price: The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates. F2 · shares: The number of securities reported represents the maximum shares that can be earned. F1 · derivative.exercise_date: The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates. F2 · derivative.underlying_shares: The number of securities reported represents the maximum shares that can be earned. F2 · balance_after: The number of securities reported represents the maximum shares that can be earned. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 16:47 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 264 | $7.47 | $1,972.08 |
DisclosureSEC source: 0001479290-24-000004 · wk-form4_1704318430.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914,718 F1 · shares: These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 16:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 48,064 | $18.91 | $908,890.24 |
DisclosureSEC source: 0001479290-23-000096 · wf-form4_169213053217251.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914,454 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 11, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 16:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 122,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-23-000096 · wf-form4_169213053217251.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 962,518 F1 · shares: Represents the vesting of a performance-based restricted stock award (PSA) granted on February 2, 2021. On August 11, 2023, the Issuer's Compensation Committee certified 100% of the PSAs eligible to vest based on (i) the achievement of a cumulative revenue goal, calculated in accordance with GAAP, adjusted to exclude revenue recognized from collaboration agreements and classified as collaboration revenue, measured beginning on January 1, 2021, provided the goal is achieved on or before the three-year anniversary of the U.S. Food and Drug Administration's approval of the Issuer's biologics license application for DAXXIFY(R) for the improvement of glabellar lines, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 17:07 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 26,279 | $22.57 | $593,151.19 |
DisclosureSEC source: 0001479290-23-000084 · wf-form4_169118325849807.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 840,375 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 10, 2023 by Mr. Foley. F2 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.93 to $22.83. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:11 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 26,279 | $24.94 | $655,332.56 |
DisclosureSEC source: 0001479290-23-000081 · wf-form4_168860585515884.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 866,654 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 10, 2023 by Mr. Foley. F3 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.73 to $25.19. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:11 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 1,000 | $15.61 | $15,606.00 |
DisclosureSEC source: 0001479290-23-000081 · wf-form4_168860585515884.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 892,933 F1 · kind: These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:09 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 31,279 | $30.72 | $960,928.41 |
DisclosureSEC source: 0001479290-23-000078 · wf-form4_168670135753126.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 891,933 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 10, 2023 by Mr. Foley. F2 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.16 to $31.13. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 00:14 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009293 · form4-06062023_120601.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,780 F1 · security: Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 10,542 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:29 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 70,447 | $34.55 | $2,433,725.46 |
DisclosureSEC source: 0001479290-23-000074 · wf-form4_168428334405537.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 923,212 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 15:22 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 5,341 | $30.65 | $163,701.65 |
DisclosureSEC source: 0001479290-23-000042 · wf-form4_167908091716141.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 818,010 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the"RSA") for 13,572 shares. The RSA vests in three equal annual installments from March 15, 2021. Read SEC document |
| March 09, 2023 Filed Mar 9, 2023 21:45 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 70,390 | $31.59 | $2,223,359.66 |
DisclosureSEC source: 0001479290-23-000034 · wf-form4_167841632767102.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 823,351 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 22:58 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000386 · form4-01042023_100145.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,550 F1 · security: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 7,312 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 16:28 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 605 | $12.18 | $7,369.20 |
DisclosureSEC source: 0001479290-23-000001 · wf-form4_167278127879359.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,092 F1 · kind: These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 19:02 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 49,274 | $26.97 | $1,328,919.78 |
DisclosureSEC source: 0001479290-22-000087 · wf-form4_166578850300322.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,487 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on October 13, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock awards ("RSA's") for 400,000 shares. The RSA's vest in three equal annual installments from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document |
| September 22, 2022 Filed Mar 9, 2023 21:45 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 175,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-23-000034 · wf-form4_167841632767102.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,741 F1 · kind: Represents settlement of a performance-based restricted stock unit ("PSU") granted on February 2, 2022. On September 22, 2022, the Company's Compensation Committee certified 100% of the PSUs eligible to vest based on i) the achievement of the U.S. Food and Drug Administration's ("FDA") approval of the Issuer's biologics license application (BLA) for DAXXIFY(R) for the improvement of glabellar lines ("FDA Approval") and ii) subject to the Reporting Person remaining in continuous service through the six-month anniversary following the date of the FDA Approval which six-month anniversary was March 7, 2023. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 18:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 1,000 | $11.75 | $11,747.00 |
DisclosureSEC source: 0001479290-22-000074 · wf-form4_165705932190547.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,761 F1 · kind: These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 23:55 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 4,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-068667 · tm2217841-5_4seq1.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,602 F1 · security: Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 9,232 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 17:54 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 3,304 | $15.79 | $52,170.16 |
DisclosureSEC source: 0001209191-22-019723 · doc4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,761 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 40,715 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 20:35 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 143,354 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001479290-22-000015 · wf-form4_164402491298660.xml · derivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,354 Underlying: Common Stock · 143,354 shares Expires 2032-02-01 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2022, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document |
| February 02, 2022 Filed May 16, 2023 20:29 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 175,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-23-000074 · wf-form4_168428334405537.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 993,659 F1 · kind: Represents settlement of a performance-based restricted stock unit ("PSU") granted on February 2, 2022. On May 12, 2023, the Issuer's Compensation Committee certified 100% of the PSUs eligible to vest based on pre-established criteria related to the price of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.